GfK:蘋果(AAPL.US)iPhone 15系列上市當月銷量按年跌6%
市場研究機構GfK數據顯示,蘋果(AAPL.US)iPhone 15系列在上市當月銷量較去年下降6%,IDC數據亦指,蘋果第三季出貨量下降4%,顯示華為正在搶佔蘋果的市佔率。
GfK稱,華為Mate 60系列上市當月銷量接近150萬部,較去年同期增長逾一倍,GfK中國高級分析師Hayden Hou表示,在華為銷售強勁下,iPhone 15系列銷量下降6%,預計華為Mate 60系列未來將繼續保持強勁的銷售勢頭。
Counterpoint Research及Jefferies 分析師本月稍早公布的中國初步銷售數據顯示,由於中國經濟放緩打擊消費者需求,蘋果的銷售跌幅可能高達雙位數字。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.